Press Releases

Biothera’s Investigational Cancer Immunotherapy Imprime PGG Neutralizes Cancer Defense Mechanisms in the Tumor Microenvironment

New Preclinical Data to be presented today at Keystone Symposium in Montreal EAGAN, MN, March 9, 2015 — New preclinical research from Biothera further demonstrates the ability of its cancer immunotherapy drug candidate Imprime PGG® to initiate a cascade effect of immune responses that neutralize cancer-associated immunosuppression in the tumor microenvironment. Biothera will present the new data today in Montreal at the Keystone Symposium: Dendritic...

Read More

Biothera Immunotherapy Binds to Multiple Immune Cell Receptors to Kill Cancer

Researchers to Present New Data at Keystone Symposia on Tumor Immunology EAGAN, MN, February 10, 2015 — Biothera’s late stage cancer immunotherapy drug binds to multiple innate immune cell receptors to exert enhanced cytotoxicity against tumor cells. Researchers will present new data showing Imprime PGG® binds to Fc gamma receptors (FcγR) in addition to complement receptor 3 (CR3) on human neutrophils and monocytes at a...

Read More

Page 6 of 6« First...23456